Picture of Avicanna logo

AVCN Avicanna Share Price

0.000.00%
ca flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapMomentum Trap

Momentum

Relative Strength (%)
1m-16.55%
3m-17.25%
6m-17.34%
1yr-13.91%
Volume Change (%)
10d/3m-3.63%
Price vs... (%)
52w High-40%
50d MA-14.61%
200d MA-10.75%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-70.72%
Return on Equity-2191.52%
Operating Margin-31.3%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Avicanna EPS forecast chart

Profile Summary

Avicanna Inc. is a Canada-based commercial-stage international biopharmaceutical company. The Company's scientific platform commercializes over thirty products across various market segments: Medical Cannabis & Wellness Products (RHO Phyto), Pharmaceutical Pipeline and Medical Cannabis Care Platform (MyMedi.ca). RHO Phyto formulary offers a diverse range of proprietary formulations, including oral, sublingual, topical and transdermal delivery. It has developed a pipeline of patent-pending drug candidates that are indication specific and in various stages of clinical development and commercialization. These cannabinoid-based drug candidates look to address unmet medical needs in the areas of dermatology, chronic pain and various neurological disorders. Its first pharmaceutical preparation (Trunerox) is in the drug registration stage in South America. MyMedi.ca is a medical cannabis care platform that serves medical cannabis patients’ needs and enhances the patient's journey.

Directors

    Last Annual
    December 31st, 2023
    Last Interim
    March 31st, 2024
    Incorporated
    November 25th, 2016
    Public Since
    July 18th, 2019
    No. of Employees
    38
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    ca flag iconToronto Stock Exchange
    Shares in Issue
    97,601,896

    AVCN Share Price Performance

    Upcoming Events for AVCN

    Q2 2024 Avicanna Inc Earnings Release

    Q3 2024 Avicanna Inc Earnings Release

    Similar to AVCN

    Picture of AEterna Zentaris logo

    AEterna Zentaris

    ca flag iconToronto Stock Exchange

    Picture of Antibe Therapeutics(Pre-Merger) logo

    Antibe Therapeutics(Pre-Merger)

    ca flag iconToronto Stock Exchange

    Picture of Appili Therapeutics logo

    Appili Therapeutics

    ca flag iconToronto Stock Exchange

    Picture of Aptose Biosciences logo

    Aptose Biosciences

    ca flag iconToronto Stock Exchange

    Picture of Briacell Therapeutics logo

    Briacell Therapeutics

    ca flag iconToronto Stock Exchange

    FAQ